Literature DB >> 19666645

Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.

Michelle Michels1, Osama I I Soliman, Judith Phefferkorn, Yvonne M Hoedemaekers, Marcel J Kofflard, Dennis Dooijes, Danielle Majoor-Krakauer, Folkert J Ten Cate.   

Abstract

AIMS: To investigate the outcome of cardiac evaluation and the risk stratification for sudden cardiac death (SCD) in asymptomatic hypertrophic cardiomyopathy (HCM) mutation carriers. METHODS AND
RESULTS: Seventy-six HCM mutation carriers from 32 families identified by predictive DNA testing underwent cardiac evaluation including history, examination, electrocardiography, Doppler echocardiography, exercise testing, and 24 h Holter monitoring. The published diagnostic criteria for HCM in adult members of affected families were used to diagnose HCM. Thirty-three (43%) men and 43 (57%) women with a mean age of 42 years (range 16-79) were examined; in 31 (41%) HCM was diagnosed. Disease penetrance was age related and men were more often affected than women (P = 0.04). Myosin Binding Protein C (MYBPC3) mutation carriers were affected at higher age than Myosin Heavy Chain (MYH7) mutation carriers (P = 0.01). Risk factors for SCD were present in affected and unaffected carriers.
CONCLUSION: Hypertrophic cardiomyopathy was diagnosed in 41% of carriers. Disease penetrance was age dependent, warranting repeated cardiologic evaluation. The MYBPC3 mutation carriers were affected at higher age than MYH7 mutation carriers. Risk factors for SCD were present in carriers with and without HCM. Follow-up studies are necessary to evaluate the effectiveness of risk stratification for SCD in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666645     DOI: 10.1093/eurheartj/ehp306

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  25 in total

1.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

2.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

3.  Cardiomyopathies: a revolution in molecular medicine and cardiac imaging.

Authors:  F J Ten Cate
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

4.  Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers.

Authors:  John D Groarke; Patrycja Z Galazka; Allison L Cirino; Neal K Lakdawala; Jens J Thune; Henning Bundgaard; E John Orav; Robert A Levine; Carolyn Y Ho
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-10-01       Impact factor: 6.875

5.  Managing uncertainty in inherited cardiac pathologies-an international multidisciplinary survey.

Authors:  Terri Patricia McVeigh; Luke J Kelly; Elizabeth Whitmore; Tara Clark; Brendan Mullaney; David E Barton; Alana Ward; Sally Ann Lynch
Journal:  Eur J Hum Genet       Date:  2019-04-12       Impact factor: 4.246

6.  The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy.

Authors:  T Germans; R Nijveldt; W P Brouwer; J G J Groothuis; A M Beek; M J W Götte; A C van Rossum
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

Review 7.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

8.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

9.  Familial hypertrophic cardiomyopathy: is the Frank-Starling law kaput?

Authors:  Sabine Huke; Björn C Knollmann
Journal:  Circ Res       Date:  2013-05-24       Impact factor: 17.367

10.  Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.

Authors:  Anne Marie Valente; Neal K Lakdawala; Andrew J Powell; Sarah P Evans; Allison L Cirino; E John Orav; Calum A MacRae; Steven D Colan; Carolyn Y Ho
Journal:  Circ Cardiovasc Genet       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.